Last update 01 Nov 2024

complications; implant, orthopedic

Last update 01 Nov 2024

Basic Info

Synonyms

Introduction-

Drugs associated with complications; implant, orthopedic

Fluorine-18 Maltodextrin

Target-

Mechanism

PET imaging

Active Org.

Emory University

Originator Org.-

Active Indication

complications; implant, orthopedic

Inactive Indication-

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with complications; implant, orthopedic

NCT05284331 / TerminatedNot Applicable

Outcome of Old Patient With Articular With Articular Implant Infection

Articular Implant Infection (AII) is itself a complicated diagnosis and a challenging condition to treat. In elderly patients, the application of existing recommendations is impeded by multiple frailties For a better knowledge of the long-term consequences of AII in elderly patient, the investigators conduct a prospective, multicentric study, whitch aim this is to better evaluate the burden of AII on elderly patients, in terms of quality of life. Secondly, the investigators would like to identify the factors that influence the prognosis, in order to guide further prospective research.

Start Date03 Mar 2021

Sponsor / Collaborator-

100 Clinical Results associated with complications; implant, orthopedic

100 Translational Medicine associated with complications; implant, orthopedic

0 Patents (Medical) associated with complications; implant, orthopedic

Literatures (Medical) associated with complications; implant, orthopedic

01 Mar 2024·Maedica

Molecular Mechanisms of Biofilm Formation on Orthopaedic Implants: Review of the Literature.

Author: Pneumaticos, Spiros ; Vlamis, John ; Sipsas, Nikolaos ; Ampadiotaki, Margarita-Michaela ; Bakalakos, Matthaios ; Vlachos, Christos

Orthopaedic implant-associated infections (OIAIs) is one of the most catastrophic complications following joint arthroplasty or fracture fixation. Given the increasing number of orthopaedic implants which are used annually, periprosthetic infections emerge as a global problem. Their diagnosis and consequent therapeutic management remain challenging for clinicians. Biofilm formation is a complex and only partially understood process that has not been extensively studied. Understanding the underlying mechanisms involved in biofilm formation is crucial in the amelioration of both diagnosis and therapeutic management of OIAIs. We performed a literature review of the molecular mechanisms of biofilm formation and discussed the four most common and thoroughly researched microbes of biofilm-related OIAIs.

01 Dec 2023·Journal of Orthopaedic Research

In vitro and in vivo assessment of extended duration cathodic voltage‐controlled electrical stimulation for treatment of orthopedic implant‐associated infections

Article

Author: Duquin, Thomas ; Ehrensberger, Mark T ; Weeks, Kyle ; Mohanraj, Gowtham ; McDermott, Eric ; Tobias, Menachem ; Titus, Albert ; Clark, Caelen

AbstractEffective treatment of orthopedic implant‐associated infections (IAIs) remains a clinical challenge. The in vitro and in vivo studies presented herein evaluated the antimicrobial effects of applying cathodic voltage‐controlled electrical stimulation (CVCES) to titanium implants inoculated with preformed bacterial biofilms of methicillin‐resistant Staphylococcus aureus (MRSA). The in vitro studies showed that combining vancomycin therapy (500 µg/mL) with application of CVCES at −1.75 V (all voltages are with respect to Ag/AgCl unless otherwise stated) for 24 h resulted in 99.98% reduction in the coupon‐associated MRSA colony‐forming units (CFUs) (3.38 × 103 vs. 2.14 × 107CFU/mL, p < 0.001) and a 99.97% reduction in the planktonic CFU (4.04 × 104 vs. 1.26 × 108CFU/mL, p < 0.001) as compared with the no treatment control samples. The in vivo studies utilized a rodent model of MRSA IAIs and showed a combination of vancomycin therapy (150 mg/kg twice daily) with CVCES of −1.75 V for 24 h had significant reductions in the implant associated CFU (1.42 × 101 vs. 1.2 × 106 CFU/mL, p < 0.003) and bone CFU (5.29 × 101 vs. 4.48 × 106 CFU/mL, p < 0.003) as compared with the untreated control animals. Importantly, the combined 24 h CVCES and antibiotic treatments resulted in no implant‐associated MRSA CFU enumerated in 83% of the animals (five out of six animals) and no bone‐associated MRSA CFU enumerated in 50% of the animals (three out of six animals). Overall, the outcomes of this study have shown that extended duration CVCES therapy is an effective adjunctive therapy to eradicate IAIs.

01 Nov 2023·Carbohydrate Polymers

Thermosensitive injectable dual drug-loaded chitosan-based hybrid hydrogel for treatment of orthopedic implant infections

Article

Author: Najafpour-Darzi, Ghasem ; Akhlaghi, Neda

A myriad of therapeutic agents and drug delivery systems are available to the surgeons for treating orthopedic implant-associated infections (OIAI), but only very few have demonstrated their effectiveness in preventing bacteria colonization and biofilm formation due to challenges in the local and sustainable therapeutic release. To address this issue, in this work, a thermosensitive injectable hydrogel based on chitosan (CH)-integrated hydroxyapatite nanoparticles (HAP NPs) containing vancomycin (Van) and quercetin (QC)-loaded in F127 micelles (CH-HAP-FQ-Van hydrogel) was fabricated with potential application in the treatment of OIAI. This dual drug delivery system demonstrated a pH-sensitive drug release pattern. In addition, 100 % growth inhibition of Staphylococcus aureus for a duration of 14 days was observed. Apart from the strong antioxidant activities owing to the co-administration of QC even after 432 h, this composite hydrogel revealed 95.88 ± 2.8 % S. aureus biofilm eradication. By consideration of degradation stability (53.52 ± 4.24 %) during 60 days along with smart gelation within 10 min at 37 °C and easy injectability, CH-HAP-FQ-Van hydrogel could be used as a promising ideal local drug delivery system for implant-related infections.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

complications; implant, orthopedic

Basic Info

Related

Analysis